Biodexa Pharmaceuticals press release (NASDAQ:BDRX): FY Biodexa generated consolidated total gross revenue of £0.38m Net cash outflow from operating activities in 2023 was £6.83m (2022: outflow £7.05...
Source Linkseekingalpha04-20
Biodexa Pharmaceuticals press release (NASDAQ:BDRX): FY Biodexa generated consolidated total gross revenue of £0.38m Net cash outflow from operating activities in 2023 was £6.83m (2022: outflow £7.05...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Terms and Conditions·Privacy Policy
Company: TTMF Limited. Tech supported by Xiangshang Yixin.
Email:uservice@ttm.financial